Pellkofer, Hannah Luise

[["dc.bibliographiccitation.firstpage","e407"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e418"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Harmel, Jens"],["dc.contributor.author","Zimmermann, Hanna"],["dc.contributor.author","Brandt, Alexander U."],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Haarmann, Axel"],["dc.contributor.author","Buttmann, Mathias"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Schroeder, Christoph"],["dc.contributor.author","Ayzenberg, Ilya"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Rommer, Paulus"],["dc.contributor.author","Weber, Martin S."],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Röpke, Luise"],["dc.contributor.author","Geis, Christian"],["dc.contributor.author","Retzlaff, Nele"],["dc.contributor.author","Zettl, Uwe"],["dc.contributor.author","Deppe, Michael"],["dc.contributor.author","Klotz, Luisa"],["dc.contributor.author","Young, Kim"],["dc.contributor.author","Stellmann, Jan-Patrick"],["dc.contributor.author","Kaste, Matthias"],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Marouf, Wael"],["dc.contributor.author","Lauda, Florian"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Graf, Jonas"],["dc.contributor.author","Klistorner, Alexander"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Albrecht, Philipp"],["dc.date.accessioned","2020-12-10T18:41:46Z"],["dc.date.available","2020-12-10T18:41:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1212/WNL.0000000000008684"],["dc.identifier.eissn","1526-632X"],["dc.identifier.issn","0028-3878"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77670"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e71500"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Pellkofer, Hannah L."],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Hauer, Daniela"],["dc.contributor.author","Schelling, Gustav"],["dc.contributor.author","Azad, Shahnaz C."],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Magerl, Walter"],["dc.contributor.author","Huge, Volker"],["dc.date.accessioned","2018-11-07T09:21:20Z"],["dc.date.available","2018-11-07T09:21:20Z"],["dc.date.issued","2013"],["dc.description.abstract","Recurrent myelitis is one of the predominant characteristics in patients with neuromyelitis optica (NMO). While paresis, visual loss, sensory deficits, and bladder dysfunction are well known symptoms in NMO patients, pain has been recognized only recently as another key symptom of the disease. Although spinal cord inflammation is a defining aspect of neuromyelitis, there is an almost complete lack of data on altered somatosensory function, including pain. Therefore, eleven consecutive patients with NMO were investigated regarding the presence and clinical characteristics of pain. All patients were examined clinically as well as by Quantitative Sensory Testing (QST) following the protocol of the German Research Network on Neuropathic Pain (DFNS). Additionally, plasma endocannabinoid levels and signs of chronic stress and depression were determined. Almost all patients (10/11) suffered from NMO-associated neuropathic pain for the last three months, and 8 out of 11 patients indicated relevant pain at the time of examination. Symptoms of neuropathic pain were reported in the vast majority of patients with NMO. Psychological testing revealed signs of marked depression. Compared to age and gender-matched healthy controls, QST revealed pronounced mechanical and thermal sensory loss, strongly correlated to ongoing pain suggesting the presence of deafferentation-induced neuropathic pain. Thermal hyperalgesia correlated to MRI-verified signs of spinal cord lesion. Heat hyperalgesia was highly correlated to the time since last relapse of NMO. Patients with NMO exhibited significant mechanical and thermal dysesthesia, namely dynamic mechanical allodynia and paradoxical heat sensation. Moreover, they presented frequently with either abnormal mechanical hypoalgesia or hyperalgesia, which depended significantly on plasma levels of the endogenous cannabinoid 2-arachidonoylglycerole (2-AG). These data emphasize the high prevalence of neuropathic pain and hyperalgesia in patients with NMO. The degree of mechanical hyperalgesia reflecting central sensitization of nociceptive pathways seems to be controlled by the major brain endocannabinoid 2-AG."],["dc.identifier.doi","10.1371/journal.pone.0071500"],["dc.identifier.isi","000326473200051"],["dc.identifier.pmid","23951176"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9229"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29084"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","The Major Brain Endocannabinoid 2-AG Controls Neuropathic Pain and Mechanical Hyperalgesia in Patients with Neuromyelitis Optica"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e1184"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e1196"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Schöppe, Louisa M."],["dc.contributor.author","Bellmann-Strobl, Judith"],["dc.contributor.author","Siebert, Nadja"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Duchow, Ankelien"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.authorgroup","on behalf of the Neuromyelitis Optica Study Group (NEMOS)"],["dc.date.accessioned","2022-04-01T10:02:06Z"],["dc.date.available","2022-04-01T10:02:06Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19–83] years, median disease duration 7 [0–43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0–8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225–68,293 or US dollars [USD] 70,297, 95% CI 60,445–80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65–0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45–0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946–160,336 or USD 153,031, 95% CI 120,296–189,196). The HRQoL revealed a negative correlation to disease severity (ρ = −0.69, 95% CI −0.76 to −0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13–0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. Discussion These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life."],["dc.identifier.doi","10.1212/WNL.0000000000200052"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105822"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease"],["dc.title.alternative","CHANCE\n NMO\n Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]